Exicure
About
Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
- 1 - 10
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $20M
- Industries
- Biotechnology,Genetics,Life Science,Therapeutics
- Founded date
- Jan 1, 2009
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 6, 2017 | Series Unknown | $11.20M | 1 | — | — | Detail |
| Sep 27, 2017 | Series Unknown | $20M | 2 | — | — | Detail |
| Oct 21, 2015 | Series Unknown | $14.79M | 1 | — | — | Detail |
| Dec 21, 2011 | Series B | $5.40M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series Unknown |
Tempus
|
— | Series Unknown |
Katalyst Securities
|
— | Series Unknown |
Abbott Biotech Ventures
|
— | Series B |
